Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 20/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.86 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.78 |
| ▸ | APLNR | P35414 | 1/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.78 |
| ▸ | GLP1R | P43220 | 1/20 | 0.78 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.78 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.78 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20547884 | 1.00 | GNRHR (0.86) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL21694888 | 0.95 | GNRHR (0.84) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL30153581 | 0.93 | GNRHR (0.84) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL21132894 | 0.93 | GNRHR (0.79) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL29707992 | 0.93 | GNRHR (0.79) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL31110348 | 0.93 | GNRHR (0.79) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL21132895 | 0.93 | GNRHR (0.79) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL26928891 | 0.93 | GNRHR (0.79) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL23193840 | 0.92 | GNRHR (0.86) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL21132899 | 0.92 | GNRHR (0.86) | GNRHRCYP3A4ADRB2APLNROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114790178-B | Preparation method of oxaagoli sodium | 福安药业集团宁波天衡制药有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-114790178-A | Preparation method of oxa-goril sodium | 福安药业集团宁波天衡制药有限公司 | 2022-07-26 | — | — | CN | claimed |
| CN-114790178-B | Preparation method of oxaagoli sodium | 福安药业集团宁波天衡制药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20220242831-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES | DR. REDDY'S LABORATORIES LIMITED (IN) | 2022-08-04 | — | — | US | disclosed |
| CN-114790178-A | Preparation method of oxa-goril sodium | 福安药业集团宁波天衡制药有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-109810065-B | Synthesis method of oxaagolide | 安徽华胜医药科技有限公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-3724167-A1 | PROCESS FOR PREPARING ELAGOLIX | Synthon B.V. (NL) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019115019-A1 | PROCESS FOR PREPARING ELAGOLIX | SYNTHON B.V. (NL) | 2019-06-20 | — | — | WO | disclosed |
| WO-2018198086-A1 | PROCESS FOR THE PREPARATION OF ELAGOLIX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LUPIN LIMITED (IN) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242831-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES | PCSK9, XPO5, HAX1 | GNRHR 1142/4885CYP3A4 836/4885ADRB2 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.